A Polish woman leads a team working on the creation of a coronavirus vaccine

Microbiologist Dr. Mariola Fotin-Mlecek leads an international team that is working on the invention of a coronavirus vaccine. In the "Facts by Facts" program, she announced that the vaccine should be ready for human testing between June and July.
An innovative coronavirus vaccine. Only natural mechanisms
Dr. Mariola Fotin-Mlecek, a native of Poland, is the head of the technology department of the German company CureVac. She oversees the development of a completely new generation of vaccines based on RNA, ribonucleic acid.

"The ribonucleic acid molecule contains information about the structure of the protein on the surface of the virus," explains researcher TVN24.

The method is innovative and has great potential.
The coronavirus vaccine offered by CureVac has another big advantage: it is quite easy to modify. So if the coronavirus mutates in the future, it can be adapted to the new genetic diversity of the pathogen.

Read it too: Coronavirus has different mutations. Has a more dangerous type arrived in Italy?
When will the vaccine be ready and who will be the first to use it?
Preparation of the coronavirus vaccine for the first trials began in January. Production started two weeks ago. Now animal testing and vaccine production are running in parallel. The first results obtained by the laboratory confirm that the team of Dr. Fotin-Molecke is on a very good path. The vaccine causes an adequate immune response, stimulates the production of a large number of antibodies.

- The results are very recent. Here are the results we got after the first dose of this vaccine. We expect that probably two doses will be needed, because we also knew about this during our previous studies of the rabies vaccine in humans. We were very surprised that after just one dose, three weeks after taking it, we observe such a high level of antibodies," says the researcher.

If all goes according to plan, human trials will begin in late June or early July. The first test results should be received in the fall, which will answer the question of whether the vaccine is effective and safe. The purpose of the first phase study is to determine what the appropriate dose will be. These studies should be conducted in different age groups, since a vaccine tested only on young people cannot be approved for use in the elderly.

- As soon as we set the dosage, and we are counting on autumn here, we will be able to start the second stage of research. Then we will be able to get vaccinated very quickly and in large quantities. We will work closely with regulatory authorities to consider whether such a vaccine can be allowed for people from vulnerable populations, such as medical personnel. This would be the first group that could benefit from such a vaccine," explains Dr. Mariola Fotin-Mlecek in "Fakt po Faktach po Faktach". Watch UK online porn https://mat6tube.com/ Diana Dali, Patty Michova, Alina Henessy, Kira Queen etc.